RecruitingNCT05447169

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population


Sponsor

Sun Yat-sen University

Enrollment

11,625 participants

Start Date

Jul 10, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.


Eligibility

Sex: MALEMin Age: 30 YearsMax Age: 62 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether blood tests for Epstein-Barr virus (EBV) antibodies and EBV DNA can be used to screen for nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat) in high-risk men in southern China before symptoms appear. **You may be eligible if...** - You are a male between 30 and 62 years old - You live in southern China - You have at least one first-degree relative (parent, sibling, or child) who had nasopharyngeal carcinoma - You have no personal history of nasopharyngeal carcinoma - Your general health is good (ECOG score 0-2) **You may NOT be eligible if...** - You have a personal history of nasopharyngeal carcinoma - You have serious heart, liver, or kidney disease - You are currently on steroids or immunosuppressants, or have an active autoimmune condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEBV antibodies test

ELISA test of VCA-IgA,EBNA1-IgA,EA-IgA, Zta-IgA ,Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma

DIAGNOSTIC_TESTEBV DNA test

quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma


Locations(1)

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05447169


Related Trials